Innate immune defenses in HIV-1 infection: prospects for a novel immune therapy (Q36670882)

15 August 2017

1 reference

title

Innate immune defenses in HIV-1 infection: prospects for a novel immune therapy (English)

1 reference

15 August 2017

1 reference

Carlos J Montoya

1

1 reference

15 August 2017

Maria T Rugeles

series ordinal

2

1 reference

15 August 2017

Alan L Landay

series ordinal

3

1 reference

15 August 2017

publication date

1 October 2006

1 reference

Expert Review of Anti-infective Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

767-780

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

15 August 2017

1 reference

Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Persistent immune activation in HIV-1 infection is associated with progression to AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Protection from HIV/AIDS: the importance of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Toll-like receptors in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

The nature of the principal type 1 interferon-producing cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

NK cells and NKT cells in innate defense against viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

What does it take to make a natural killer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Strategies for target cell recognition by natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Distinct functional lineages of human V(alpha)24 natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Impaired production of cytokines is an independent predictor of mortality in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Reduced type 1 and type 2 cytokines in antiviral memory T helper function among women coinfected with HIV and HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Diversity of receptors binding HIV on dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Defective natural immunity: an early manifestation of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Interferon-alpha generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Variations in patterns of highly active antiretroviral therapy (HAART) adherence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Cell activation by monosaccharide lipid A analogues utilizing Toll-like receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Immunization with human immunodeficiency virus type 1 rgp120W61D in QS21/MPL adjuvant primes T cell proliferation and C-C chemokine production to multiple epitopes within variable and conserved domains of gp120W61D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Self-assembled hexa-peri-hexabenzocoronene graphitic nanotube

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

CpG motifs in bacterial DNA and their immune effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Murine natural killer T(NKT) cells [correction of natural killer cells] contribute to the granulomatous reaction caused by mycobacterial cell walls

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Activation of NKT cells protects mice from tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Human NKT cells express granulysin and exhibit antimycobacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

9-(2-Phosphonylmethoxyethyl) adenine increases the survival of influenza virus-infected mice by an enhancement of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Limiting dilution analysis of interleukin-2-producing T cells responsive to recall and alloantigens in human immunodeficiency virus-infected and uninfected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Comparison of the frequency of interleukin (IL)-2-, interferon-gamma-, and IL-4-producing T cells in 2 diseases, human immunodeficiency virus types 1 and 2, with distinct clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

IL-15 and HIV infection: lessons for immunotherapy and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Interleukin-15 enhances the secretion of IFN-gamma and CC chemokines by natural killer cells from HIV viremic and aviremic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.5.767

21 January 2018

Identifiers

DOI

10.1586/14787210.4.5.767

1 reference

15 August 2017

1 reference